Does the tumor tissue microarray include survival follow-up information, and can it be used for prognostic analysis?

Whether off-the-shelf chips come with follow-up data varies greatly. Some commercial chips include limited clinical annotations, such as sex, age, TNM, pathological grade, survival time, and outcome, but many have early follow-up cutoff dates or incomplete fields. Before purchasing, be sure to request the data dictionary to clarify OS/DFS, censoring definitions, follow-up cutoff dates, and whether they correspond one-to-one with spot IDs. Do not rely solely on promotional claims that follow-up is included.

If the cohort sourced from existing specimens lacks follow-up, purchasing it separately or updating it later is usually quite troublesome, because the supplier may not have the authority to continuously track the original cases, or may only be able to provide baseline pathological information. You can first ask clearly whether an optional clinical data package is available; pricing is generally charged per case or for the entire cohort, and is often higher than the tissue itself. If the other party says it can be updated later, confirm the update time points, field completeness rate, and ethics re-consent status.

If the clinical information for off-the-shelf chips is incomplete, a more reliable approach is to customize them or collaborate with the pathology department, using existing follow-up cohorts to select cores and construct the chips. You control the clinical data, while the supplier only performs punching, arrangement, and sectioning, so that follow-up quality and TNM staging can be verified according to research standards. When purchasing or supplementing follow-up data, be sure to sign data use agreements and ethical compliance documents to prevent patient privacy and research use from exceeding authorization.

For prognostic analysis, sample size and event count are critical. Before purchasing ready-to-use products, roughly estimate the required sample size based on the marker positivity rate, and prioritize catalog numbers with complete survival time, outcome, TNM stage, and pathological grade. A larger spot diameter is more favorable for scoring stability, but the core of prognostic analysis is the quality of clinical follow-up. It is recommended to first perform a scoring consistency analysis on replicate spots, determine the cutoff, and then apply the survival model, so as to avoid ignoring tumor heterogeneity.